Follow-Up for Medical Care Among Drug Users With Hepatitis C

2006 ◽  
Vol 29 (4) ◽  
pp. 355-366 ◽  
Author(s):  
Grace L. Reynolds ◽  
Dennis G. Fisher ◽  
Adi Jaffe ◽  
Jordan Edwards
Keyword(s):  
2006 ◽  
Vol 135 (3) ◽  
pp. 417-426 ◽  
Author(s):  
L. J. BRANT ◽  
M. HURRELLE ◽  
M. A. BALOGUN ◽  
P. KLAPPER ◽  
F. AHMAD ◽  
...  

This paper describes sentinel laboratory surveillance of hepatitis C antibody testing in England. Demographic and test result data were supplemented by follow-up questionnaires sent to the requesting clinician. Between October 2002 and September 2003 almost 75000 anti-HCV tests were performed in eight sentinel centres. More males were tested than females and over half of those tested were aged 25–44 years. Overall 5·7% (3333/58144, range 2·8–7·7%) individuals tested positive. Follow-up questionnaire data showed that 82% (1043/1277) of the positives had injecting drug use reported as the main risk exposure. The majority of negative individuals were undergoing routine screening as recommended for specific patient groups. Most individuals were asymptomatic. Antibody prevalence was estimated to be 34% in current injecting drug users and 42% in former injectors. Comparing positives to routine national surveillance suggests that only 53% (1782/3333) of diagnosed cases were reported. Sentinel laboratory data can provide valuable supplementary data to national surveillance.


1997 ◽  
Vol 16 (4) ◽  
pp. 339-347 ◽  
Author(s):  
MARC A. SERFATY ◽  
ANDREW LAWRIE ◽  
BELINDA SMITH ◽  
ALISON M. BRIND ◽  
JOHN P. WATSON ◽  
...  
Keyword(s):  

2002 ◽  
Vol 8 (1) ◽  
pp. 45-49 ◽  
Author(s):  
O. Dalgard ◽  
K. Bjøro ◽  
K. Hellum ◽  
B. Myrvang ◽  
K. Skaug ◽  
...  

2019 ◽  
Vol 1 (4) ◽  
pp. 27-35
Author(s):  
Andre-Jean Remy ◽  
Hakim Bouchkira ◽  
Jeremy Hervet ◽  
Arnaud Happiette ◽  
Hugues Wenger

Introduction In France 33% of patients didn’t take care of hepatitis C because there were no diagnosed. Drug injection was main contamination route of hepatitis C virus (HCV) in France. French guidelines were to treat all inmates and drug users, even fibrosis level. Access of HCV screening, care and treatment in drugs users, prisoners and homeless was low in France. They were considered as difficult to treat populations. All these patients need specific support. Hepatitis Mobile Team (HMT) was created in July 2013 to increase screening care and treatment of hepatitis B and C patients. HMT was composed of hepatologist, nurses, social workers and health care worker. Objective increase outreach screening care treatment access and cure of our target population. Patients and methods Target population was drugs users, prisoners, homeless, precarious people, migrants and psychiatric patients. We proposed part or all of our services to our 42 medical and social partners: HCV HBV screening by DBS (dried blood test); outside DBS and FIBROSCAN in converted van; Outreach open center; Drug users information and prevention, Free blood tests in primary care;, Staff training; Social screening and diagnosis; Mobile liver stiffness Fibroscan in site; Advanced on-site specialist consultation; Easy access to pre-treatment commission; Low cost mobile phones for patients; Individual psycho-educative intervention sessions; Collective educative workshops; Peer to peer educational program; Specific one day hospitalizations. All services were free for patients and for partners. Results from 2013 July to 2018 December, we did 8382 DBS for 5382 people (3053 HCV DBS) and 2302 Fibroscan*. HCV new positive rate was 21.3%. Our HCV active file was 651patients included these 24.8% new patients screened by DBS; 98% realized HCV genotype, HCV viral load and FIBROSCAN. DAA treatment was proposed to 96%; 95% started treatment, 4% were lost follow up or refused treatment. After treatment, there was 7 relapse and 3 reinfections by drug injection and cured rate of 94%. Sociological evaluation showed that 4 program qualities for patients: free access, closeness (outside hospital), speed (of the results) and availability (of nurse and social workers). Conclusions: Specific follow-up of drugs users and other HCV high-risk patients including screening, early detection, diagnosis and treatment increase rate of treated and cured patients, with low rate of relapse and reinfections.


1998 ◽  
Vol 36 (4) ◽  
pp. 872-877 ◽  
Author(s):  
Marcel Beld ◽  
Maarten Penning ◽  
Martin McMorrow ◽  
Jozef Gorgels ◽  
Anneke van den Hoek ◽  
...  

Hepatitis C virus (HCV) infection often persists in association with chronic hepatitis. Different factors have been proposed to determine the clinical outcome of HCV infection. The aim of this study was to examine three different factors of HCV infection among injecting drug users. Nineteen untreated HCV seroconverters were tested longitudinally for the presence of HCV RNA by reverse transcriptase (RT) PCR, and results were quantified by the branched-DNA (bDNA) assay. HCV genotypes were determined with the first sample taken after HCV seroconversion. To assess the natural course of infection, serum alanine aminotransferase (ALT) levels were measured at three stages in every individual. The concordance between bDNA and RT-PCR was 98.9%. Three distinct patterns were found, according to the HCV RNA load after seroconversion during a mean follow-up period of 5 years (range, 1 to 8 years). HCV genotype 1a was predominant (52.6%). There was a significant increase in serum ALT levels (mean 55.5 U/liter) in the early phase of HCV infection, compared with basal serum ALT levels before HCV seroconversion and at the end of the follow-up period. Three distinct HCV RNA load profiles were found, without apparent relationship to genotype and serum ALT levels in the first 5 years of HCV infection.


Sign in / Sign up

Export Citation Format

Share Document